Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on ...
GlobalData on MSN1d
Palatin’s UC therapy prompts clinical remission in a third of patientsA third of patients with active ulcerative colitis (UC) experienced clinical remission in a Phase II trial of Palatin ...
Body mass index did not impact the safety and efficacy of etrasimod in patients with ulcerative colitis, according to 2 studies.
ABIVAX is a French biotech with a novel ulcerative colitis treatment in phase 3 trials. Click here to find out why I am ...
Recommendation based on the findings from the Phase 3 studies (GALAXI programme and GRAVITI) in Crohn's disease 1,2< ...
Guselkumab is the first and only interleukin-23 inhibitor that offers both subcutaneous and intravenous induction options for ...
Technologies announced positive topline results from its Phase 2 study of PL8177, a selective melanocortin-1 receptor agonist, in ...
Equillium's itolizumab showed improved longer-term outcomes in aGVHD despite missing primary endpoints. FDA feedback on ...
Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to ...
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...
Eli Lilly has the results it was looking for in a second, confirmatory trial of its anti-IL-23p19 antibody mirikizumab in ulcerative colitis as ... symptomatic, endoscopic and histologic endpoints ...
Health and Me on MSN5d
FDA Approves Tremfya For Active Crohn's DiseaseCrohn's disease is a type of inflammatory bowel disease (IBD) that causes swelling and irritation of the tissues, called ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback